Global biotechnology industry needs new paradigm for drug R&D

The global biotechnology industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp increase in funds raised.

However, much of the industry's growth was driven by a relatively small group of commercial-stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts. These and other findings were released in Beyond borders: unlocking value, Ernst & Young’s (EY) 28th annual biotechnology industry report.